JWK002

Phase 1Small molecule

WWest China Hospital

JWK002 is one of 2 small molecule programs targeting Retinoschisis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

RetinoschisisActive, not recruiting

RetinoschisisPhase 1

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Retinoschisis

#DrugCompanyPhaseTrials

Diamox

Teva

Phase 2

1 2

JWK002

WWest China Hospital

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2033

Phase 1Recruiting

Retinoschisis

NCT06345898

Clinical

Trials by Indication[1]

Retinoschisis1 trial

Safety and Efficacy of a Single Subretinal Injection of JWK002 Gene Therapy in Subjects With X-linked Retinoschisis(XLRS)

Recruiting·WWest China Hospital·Phase 1·NCT06345898·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for JWK002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JWK002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JWK002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — West China Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: WWest China Hospital

JWK002

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2033

Trials by Indication[1]

Retinoschisis1 trial

References

Drug Info

Quick Facts

Related News